Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06610643
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-22
Brief Title:
Extended Remdesivir Infusion Combined With NirmatrelvirRitonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Extended Remdesivir Infusion Combined With NirmatrelvirRitonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SARS-CoV-2
Brief Summary:
To evaluate the safety and efficacy of extended remdesivir infusion targeting on immunocompromised individuals who had positive SARS-CoV-2 PCR despite an oral antiviral agent prescription
Detailed Description:
Prolonged viral shedding is commonly observed in immunocompromised patients infected by SARS-CoV-2 Until now there is no successful clinical trial or guideline to guide optimal treatment for this clinical condition Here we aimed to establish a clinical trial with combination of prolonged remdesivir infusion with nirmatrelvirritonavir among COVID-19 patients recently receiving b-cell depletion therapy to evaluate to clinical outcomes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None